Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Frontiers in Oncology
|
July 15, 2014
Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells
Jun Gong, Monica M Mita
British Journal of Cancer
|
September 29, 2020
Bromodomain inhibitors a decade later: a promise unfulfilled?
Monica M Mita, Alain C Mita
Current Oncology Reports
|
June 26, 2007
The role of mTOR inhibitors for treatment of sarcomas
Monica M Mita, Anthony W Tolcher
Clinical Breast Cancer
|
July 17, 2003
Mammalian target of rapamycin: a new molecular target for breast cancer
Monica M Mita, Alain Mita, Eric K Rowinsky
Expert Review of Clinical Pharmacology
|
August 27, 2013
Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas
Monica M Mita, Jun Gong, Sant P Chawla
Cancer Biology & Therapy
|
September 26, 2003
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer
Monica M Mita, Alain Mita, Eric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2012
Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Alain C Mita, Robert Figlin, Monica M Mita
Clinical Colorectal Cancer
|
August 3, 2004
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer
Alain C Mita, Monica M Mita, Eric K Rowinsky
World Journal of Methodology
|
March 29, 2016
Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity
Jun Gong, Esha Sachdev, Alain C Mita, et al.
Expert Opinion on Investigational Drugs
|
January 16, 2013
Vascular-disrupting agents in oncology
Monica M Mita, Liza Sargsyan, Alain C Mita, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Frontiers in Oncology
|
July 15, 2014
Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells
Jun Gong, Monica M Mita
British Journal of Cancer
|
September 29, 2020
Bromodomain inhibitors a decade later: a promise unfulfilled?
Monica M Mita, Alain C Mita
Current Oncology Reports
|
June 26, 2007
The role of mTOR inhibitors for treatment of sarcomas
Monica M Mita, Anthony W Tolcher
Clinical Breast Cancer
|
July 17, 2003
Mammalian target of rapamycin: a new molecular target for breast cancer
Monica M Mita, Alain Mita, Eric K Rowinsky
Expert Review of Clinical Pharmacology
|
August 27, 2013
Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas
Monica M Mita, Jun Gong, Sant P Chawla
Cancer Biology & Therapy
|
September 26, 2003
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer
Monica M Mita, Alain Mita, Eric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2012
Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Alain C Mita, Robert Figlin, Monica M Mita
Clinical Colorectal Cancer
|
August 3, 2004
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer
Alain C Mita, Monica M Mita, Eric K Rowinsky
World Journal of Methodology
|
March 29, 2016
Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity
Jun Gong, Esha Sachdev, Alain C Mita, et al.
Expert Opinion on Investigational Drugs
|
January 16, 2013
Vascular-disrupting agents in oncology
Monica M Mita, Liza Sargsyan, Alain C Mita, et al.
Page
of 5